

Table 1. Current Clinical Trials

Trial	Trial Registry Identifier(s)	Sponsor(s)	Phase	Estimated End Date/Interim Results
ADOPTIVE IMMUNOTHERAPY				
AutoRESIST: HIV antigen-specific T-cells targeting conserved epitopes for treatment of HIV-associated lymphoma	NCT04975698	Catherine Bollard, Children's Research Institute	Phase II	June 2026
AlloRESIST: Evaluate the safety, immunologic, and virologic responses of donor derived HIV-specific T-cells in HIV+ individuals following allogeneic bone marrow transplantation	NCT04248192	Catherine Bollard, Children's Research Institute	Phase I	April 2025
HST-NEETs: HIV-1 specific T-cells for HIV+ individuals	NCT03485963 (closed to enrollment)	Children's Research Institute	Phase I	December 2024
ANALYTICAL TREATMENT INTERRUPTION				
Assessment of HIV remission in early treated individuals with the MHC B35/53Bw4TTC2 genotype	NCT05482854	ANRS	N/A	July 2025
SCOPE-ATI	NCT04359186	UCSF	N/A	June 2024 CROI 2024, Abstracts 446 , 482 Strategies for an HIV Cure 2023 , Abstract PP64
Imaging and biopsy of individuals undergoing ATI	NCT05419024	National Cancer Institute (NCI)	Phase II	August 2026 CROI 2024, Abstract 502 Strategies for an HIV Cure 2023 , Abstract PP41 Front Med. 2022 Aug 22;9:979756 .
ANTI-α4β7 INTEGRIN ANTIBODIES				
vedolizumab (anti- α ₄ β ₇ integrin antibody)	NCT03147859	Ottawa Hospital Research Institute	Phase II	December 2023 BMJ Open. 2020 ; 10(10):e041359 . CROI 2019, Abstract 393

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 1. Current Clinical Trials (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated End Date/Interim Results
ANTI-INFLAMMATORY				
Fecal Microbiota Transplantation (FMT)	NCT06022406 (not yet open for enrollment)	Jean-Pierre Routy, McGill University Health Centre	Phase II	September 2025
BCL-2 ANTAGONISTS				
venetoclax	NCT05668026	University of Aarhus	Phase I/IIb	March 2026
BISPECIFIC T-CELL ENGAGERS				
GS-8588	No clinicaltrials.gov entry, listed on UPenn website	Gilead Sciences	Phase I	N/A
BROADLY NEUTRALIZING ANTIBODIES				
VRC01 (analytical treatment interruption in HVTN 703/HPTN 081 AMP trial participants)	NCT04860323	HIV Vaccine Trials Network	N/A	November 2029
VRC01 (analytical treatment interruption in HVTN 704/HPTN 085 AMP trial participants)	NCT04801758 (closed to enrollment)	HIV Vaccine Trials Network	N/A	January 2030
10-1074-LS + 3BNC117-LS in primary HIV infection	NCT04319367	Imperial College London	Phase II	July 2027 IAS HIV Cure & Immunotherapy Forum 2023 HIV Persistence Workshop 2022, Abstracts OP 7.2, PP 8.11 (slides) Trials. 2022 Apr 5;23(1):263
3BNC117-LS + 10-1074-LS	NCT06205602 (not yet open for enrollment)	AIDS Clinical Trials Group	Phase II	February 2029

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 1. Current Clinical Trials (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated End Date/Interim Results
BROADLY NEUTRALIZING ANTIBODIES (Cont.)				
3BNC117-LS + 10-1074-LS	NCT05300035	French National Agency for Research on AIDS and Viral Hepatitis (ANRS)	Phase II	December 2028
VRC07-523LS + PGT121.414.LS	NCT05719441 (not yet open for enrollment)	NIAID	Phase II	September 2028
3BNC117-LS-J + 10-1074-LS-J	NCT06031272	ACTG	Phase I	June 2026
3BNC117-LS + 10-1074-LS	NCT05612178	NIAID	Phase I	December 2025
AAV8-VRC07 (broadly neutralizing antibody delivered by AAV vector)	NCT03374202 (closed to enrollment)	NIAID	Phase I	August 2026 Nat Med. 28(5):1022-1030. CROI 2022, Abstract 498 CROI 2021, Abstract 160 , Webcast CROI 2020, Abstract 41LB , Webcast
CAP256V2LS + VRC07-523LS	PACTR202309578224660 (not yet open for enrollment)	Centre for the AIDS Programme of Research in South Africa (CAPRISA)	Phase I	October 2025
CD4 ATTACHMENT INHIBITORS				
UB-421 (antibody inhibitor of HIV binding to CD4 receptors)	NCT04404049 (not yet open for enrollment)	UBP Greater China (Shanghai) Co., Ltd	Phase II	June 2025
COMBINATIONS				
VRC07-523LS, CAP256V2LS, vesatolimod	NCT05281510 (closed to enrollment)	Gilead Sciences	Phase IIa	March 2025

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 1. Current Clinical Trials (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated End Date/Interim Results
COMBINATIONS (Cont.)				
budigalimab (anti-PD-1 antibody) +/- ABBV-382 (anti- $\alpha_4\beta_7$ integrin antibody)	NCT06032546	AbbVie	Phase II	October 2026
UB-421 + chidamide (antibody inhibitor of HIV binding to CD4 receptors + HDAC inhibitor)	NCT04985890 (not yet open for enrollment)	UBP Greater China (Shanghai) Co., Ltd	Phase II	December 2027
Ad26.Mos4.HIV, MVA-BN-HIV, PGT121, PGDM1400, VRC07-523LS (therapeutic vaccines, broadly neutralizing antibodies)	NCT04983030	Boris Juelg, MD PhD	Phase I/IIa	April 2026
ChAdOx1.tHIVconsV1, ChAdOx1.HIVconsV62, MVA.tHIVconsV3, MVA.tHIVconsV4, 3BNC117-LS, 10-1074-LS, vesatolimod	NCT06071767	NIAID	Phase I/IIa	April 2026
IMPAACT P1115 v2.0: Very early intensive treatment of infants with HIV to achieve remission (ART +/- VRC01)	NCT02140255	IMPAACT	Phase I/II	December 2031 CROI 2024, Abstracts 184 , 954 Lancet HIV. S2352-3018(23)00236-9. Strategies for an HIV Cure 2023, Abstract PP05 CROI 2022, Abstract 31
Therapeutic conserved element DNA vaccine (IL-12 adjuvanted p24CE), MVA vaccine boost (MVA/HIV62B), TLR9 agonist (lefitolimod), broadly neutralizing antibodies (VRC07-523LS + 10-1074)	NCT04357821 (closed to enrollment)	UCSF	Phase I/II	December 2024 CROI 2024, Abstracts 446 , 618 HIV Res Clin Pract. 25(1):2312318 Strategies for an HIV Cure 2023, Abstract PP66 CROI 2023, Abstract 435

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 1. Current Clinical Trials (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated End Date/Interim Results
COMBINATIONS (Cont.)				
HVRRICANE: HIVIS DNA + MVA-CMDR vaccines +/- TLR4 agonist	NCT04301154 (closed to enrollment)	PENTA Foundation	Phase I	February 2025 CROI 2024, Abstract 408
N-803 (recombinant human super agonist interleukin-15 complex) +/- VRC07-523LS + 10-1074	NCT04340596	NIAID	Phase I	April 2026
N-803, 3BNC117-LS, 10-1074-LS	NCT05245292	Rockefeller University	Phase I	December 2025
CYTOKINES				
N-803 in acute HIV infection	NCT04505501	Thai Red Cross AIDS Research Centre	Phase II	June 2025
DUAL-AFFINITY RE-TARGETING (DART) MOLECULES				
MGD020 +/- MGD014	NCT05261191 (closed to enrollment)	MacroGenics	Phase I	May 2024
GENE THERAPIES				
EBT-101 (CRISPR/Cas9 targeting HIV provirus)	NCT05144386 (closed to enrollment)	Excision BioTherapeutics	Phase I/IIa	May 2025 ESGCT Congress 2023, Abstract OR31
LVgp120duoCAR-T cells	NCT04648046	Steven Deeks, UCSF	Phase I/IIa	December 2027
Cal-1: Dual anti-HIV gene transfer construct	NCT02390297 (closed to enrollment)	Calimmune	Phase I/II	October 2031 CROI 2020, Abstract 338
An ATI study to evaluate the impact of AGT103-T to suppress HIV replication in the absence of ART	NCT05540964 (enrolling by invitation)	American Gene Technologies International Inc.	Phase I	July 2025 Front Med. 11:1342476.

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 1. Current Clinical Trials (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated End Date/Interim Results
GENE THERAPIES (Cont.)				
CD4 CAR + SB-728mR modified T cells	NCT03617198 (closed to enrollment)	University of Pennsylvania	Phase I	December 2027 CROI 2022 (James L. Riley)
Chimeric Antigen Receptor (CAR)-T cell therapy	NCT03240328	Guangzhou 8th People's Hospital	Phase I	December 2030 JCI. 2021;150211
CMV-specific HIV-CAR T Cells	NCT06252402 (not yet open for enrollment)	City of Hope Medical Center	Phase I	March 2028
EBT-101 (long-term follow-up study)	NCT05143307 (enrolling by invitation)	Excision BioTherapeutics	Phase I	April 2037
Long-term follow-up of study participants treated with AGT103-T	NCT05529342 (enrolling by invitation)	American Gene Technologies International Inc.	Phase I	September 2038
SB-728mR-HSPC (autologous hematopoietic stem/progenitor cells modified at the CCR5 gene)	NCT02500849 (closed to enrollment)	City of Hope Medical Center	Phase I	August 2024
GENE THERAPIES FOR HIV-POSITIVE PEOPLE WITH CANCERS				
Stem cells gene-modified with CCR5 shRNA/TRIM5alpha/TAR decoy	NCT02797470 (closed to enrollment)	AIDS Malignancy Consortium	Phase I/II	June 2025
Stem cells gene-modified to encode multiple anti-HIV RNAs (rHIV7-shI-TAR-CCR5RZ)	NCT02337985 (closed to enrollment)	City of Hope Medical Center	Phase I	December 2024
Stem cells gene-modified to encode multiple anti-HIV RNAs (rHIV7-shI-TAR-CCR5RZ) + busulfan	NCT01961063 (closed to enrollment)	City of Hope Medical Center	Phase I	December 2024
IMAGING STUDIES				
Imaging immune activation in HIV by PET-MR	NCT03684655	University of California, San Francisco	Phase I	November 2024 CROI 2024, Abstract 105
Radiolabeled VRC01	NCT03729752	University of California, San Francisco	Phase I	January 2025 Nat Commun. 2022;13(1):1219. CROI 2020, Abstract 72

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 1. Current Clinical Trials (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated End Date/Interim Results
IMMUNE CHECKPOINT INHIBITORS				
ASC22 (anti-PD-L1 antibody)	NCT05330143	Asclepis Pharmaceuticals Co., Ltd.	Phase II	December 2023
NIVO-LD : Low dose nivolumab in adults living with HIV on antiretroviral therapy	NCT05187429	University of Melbourne	Phase I/II	January 2026
nivolumab (anti-PD-1 antibody) + ipilimumab (anti-CTLA-4 antibody) in treating patients with advanced HIV associated solid tumors	NCT02408861	National Cancer Institute (NCI)	Phase I	July 2024 Cancer. 2023 Nov 14. Clin Infect Dis. 2021 ciaa1530 HIV Persistence Workshop 2019, Abstract OP 5.5 J. Clin Oncol 36, no. 15 suppl
pembrolizumab (anti-PD-1 antibody) in treating patients with HIV and relapsed, refractory, or disseminated malignant neoplasms	NCT02595866 (closed to enrollment)	National Cancer Institute (NCI)	Phase I	October 2024 CROI 2023, Abstract 181 Sci Transl Med. 14(629): eabl3836 JAMA Oncol. Sep 1;5(9):1332-1339 CROI 2019, Abstract 27 CROI 2018, Abstract 656LB
IMMUNOMODULATORS				
lenalidomide, adenosylmethionine	NCT05598580	First Affiliated Hospital of Zhejiang University	Phase IV	November 2024
JANUS KINASE INHIBITORS				
baricitinib	NCT05452564	Emory University	Phase II	January 2028

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 1. Current Clinical Trials (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated End Date/Interim Results
LATENCY-REVERSING AGENTS				
lauric acid	NCT05687565	Hospital Universitari Vall d'Hebron Research Institute	N/A	December 2025
panobinostat, lenalidomide + pyrimethamine	NCT06240520 (not yet open for enrollment)	Erasmus Medical Center	Phase I/II	October 2025
topiramate	NCT06282783 (not yet open for enrollment)	Erasmus Medical Center	Phase I/II	August 2025
arsenic trioxide	NCT03980665	Guangzhou 8th People's Hospital	Phase I	December 2025
decitabine, romidepsin	NCT05230368	ANRS	Phase I	April 2026
T-CELL RECEPTOR-BASED BISPECIFICS				
IMC-M113V in HLA-A*02:01 positive people	2021-002008-11	Immunocore	Phase I/II	N/A
THERAPEUTIC VACCINES				
BELIEVE: BCG vaccination effect on latent reservoir size in treated HIV-1 infection	NCT05004038 (closed to enrollment)	University of Zurich	Phase IIa	January 2024
HB-502/HB-501 (arenavirus vaccine vectors)	NCT06430905 (not yet open for enrollment)	Hookipa Biotech GmbH	Phase Ib	November 2025
GS-1966/GS-1144 HIV vaccine regimens	No clinicaltrials.gov entry, #7 on Midway Research Center list	Gilead Sciences	Phase Ib	N/A
HIV Env mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 + MPLA-5 adjuvant (*primarily focused on preventive HIV vaccine development but may also assist cure research)	NCT06449196 (not yet open for enrollment)	IAVI	Phase I	December 2025
426c.Mod.Core-C4b, 3M-052-AF + Alum (*primarily focused on preventive HIV vaccine development but may also assist cure research)	NCT06006546	NIAID, HIV Vaccine Trials Network	Phase I	December 2025
ChAdOx1.HIVconsV62-MVA.tHIVconsV4 (C62-M4), ChAdOx1.tHIVconsV1+C62-MVA.tHIVconsV3+M4 (C1C62-M3m4)	NCT05604209	University of North Carolina, Chapel Hill	Phase I	October 2024

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 1. Current Clinical Trials (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated End Date/Interim Results
THERAPEUTIC VACCINES (Cont.)				
DC-HIV04: a1DC + inactivated whole autologous HIV, a1DC + conserved HIV peptides	NCT03758625 (closed to enrollment)	Sharon Riddler, University of Pittsburgh	Phase I	March 2025
ICVAX: PD-1-enhanced HIV DNA vaccine	NCT06253533 (closed to enrollment)	Shenzhen Immuno Cure Biomedical Company Limited	Phase I	January 2025 IAS HIV Cure & Immunotherapy Forum 2023
NETI: Trimer 4571 therapeutic vaccination	NCT04985760	NIAID	Phase I	November 2025
Therapeutic vaccine based on aDC1 dendritic cells	NCT05786937 (not yet open for enrollment)	University of Sao Paulo General Hospital	Phase I	December 2023
TREATMENT INTENSIFICATION/EARLY TREATMENT				
DGVTAf: Immediate initiation of antiretroviral therapy during "hyperacute" HIV infection	NCT02656511 (closed to enrollment)	UCSF	Phase IV	May 2028 J Clin Invest. 2024 Apr 23:e176673. medRxiv 2024.03.27.24304867 CROI 2024, Abstracts 468 , 508 IAS 2023, Abstract 2167 CROI 2023, Abstract 305
AAHIV: Antiretroviral therapy for acute HIV infection	NCT00796263	South East Asia Research Collaboration with Hawaii	Phase III	June 2033 See supplemental references page

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 1. Current Clinical Trials (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated End Date/Interim Results
TREATMENT INTENSIFICATION/EARLY TREATMENT (Cont.)				
EIT: Early infant HIV treatment in Botswana	NCT02369406 (closed to enrollment)	Harvard School of Public Health	Phase II/III	June 2029 JAIDS 2022 Dec 12 CROI 2022, Abstract 712 Clin Infect Dis. 2021 ciab143 Clin Infect Dis. 2020 Jan 12. Sci Transl Med. 2019 Nov 27;11(520). pii: eaax7350 CROI 2019, Poster abstract 826 CROI 2018, Abstract 136
EARLIER: Early ART to limit infection and establishment of reservoir	NCT02859558 (closed to enrollment)	AIDS Clinical Trials Group	Phase II	April 2025 AIDS. 2024 Mar 14. Clin Infect Dis. 2021 Aug 2;73(3):e643-e651
TYROSINE KINASE INHIBITORS				
dasatinib	NCT05527418	Eva Bonfill, Institut d'Investigacions Biomèdiques August Pi i Sunyer	Phase II	June 2026
dasatinib	NCT05780073	Fundació Institut Germans Trias i Pujol	Phase II	March 2025

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Table 2. Current Observational Studies

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated End Date/Interim Results
Accurate staging of immuno-virological dynamics during acute HIV infection (ACS)	NCT03449706	University Hospital, Ghent	N/A	January 2028
Analytic treatment interruption (ATI) to assess HIV cure	NCT02437526 (enrolling by invitation)	Mayo Clinic	N/A	May 2025 PLoS Med. 2017 Nov 28;14(11):e1002461.
ANRS CO24 OncoVIHAC: Immune checkpoint inhibitors in HIV+ individuals with cancers	NCT03354936	Inserm-ANRS	N/A	June 2022 Cells. 2022 Mar 17;11(6):1015. AIDS 2020, Abstract OAB0203
APRIL: Analysis of the persistence, reservoir and HIV latency	NCT05752318	University Hospital, Strasbourg, France	N/A	February 2027 Pathog Immun. 8(2):92-114.
ARCH: Analysis of the reservoir in individuals controlling HIV infection	NCT06016114 (not yet open for enrollment)	Sponsor University Hospital, Ghent	N/A	October 2028
ATGALIG-HIV: Study of autophagy and the effects of GALIG gene products in HIV-1+ patients on antiretroviral therapy since primary infection, chronic phase, or never treated	NCT04160455	Centre Hospitalier Régional d'Orléans	N/A	November 2039
BICTEVOIR: A study to determine the cartography of virologic reservoir related to antiretroviral concentrations in HIV-1+ patients on first line treatment containing bictegravir, emtricitabine and tenofovir alafenamide	NCT05222945 (not yet open for enrollment)	ANRS	N/A	March 2024
Characterization of acute and recent HIV-1 infections in Zurich: a long-term observational study	NCT00537966	University of Zurich	N/A	January 2025 Microorganisms. 12(2):302 CROI 2023, Abstract 387

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 2. Current Observational Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated End Date/Interim Results
CHRONO : A prospective cohort for ex vivo cure studies with chronic HIV+ patients in the Netherlands	NCT04888754 (closed to enrollment)	Erasmus Medical Center	N/A	January 2034
CODEX (the “Extreme” cohort, ANRS CO21)	NCT01520844	Inserm-ANRS	N/A	September 2023 See supplemental references page
Comparing immune activation and HIV reservoir size between PWHIV on tenofovir-containing versus NRTI-free ART	NCT05584397 (enrolling by invitation)	University of Washington	N/A	February 2025
Developing a functional cure for HIV disease: Clinical specimen collection from HIV+ individuals	NCT03215004 (closed to enrollment)	American Gene Technologies International Inc.	N/A	February 2021
Establish and characterize an acute HIV infection cohort in a high-risk population	NCT00796146	Southeast Asia Research Collaboration with Hawaii	N/A	July 2033 See supplemental references page
Evaluation of the role of HIV-1 Tat protein and anti-Tat immune response in HIV reservoir (ISS OBS T-005)	NCT04263207 (suspended)	Barbara Ensoli, MD, PhD, Istituto Superiore di Sanità	N/A	June 2025
Extended follow-up of the ISS T-003 trial volunteers (ISS T-003 EF-UP2020)	NCT05680948	Istituto Superiore di Sanità	N/A	June 2024
EX VIVO : Ex vivo characterization and targeting of the latent HIV infected reservoir to cure HIV	NCT05215704	Erasmus Medical Center	N/A	December 2030
FRESH (Females rising through education, support, and health)	Ragon Institute webpage (no clinicaltrials.gov entry)	Ragon Institute of MGH, MIT and Harvard	N/A	N/A See supplemental references page
HI-ART : Optimising cohorts for HIV cure interventions	NCT05852301	Bayside Health	N/A	December 2025
HIV-Mercuri : HIV study on measuring the reservoir on cellular level to cure infection	NCT04305665	University Hospital, Ghent	N/A	December 2025
HUSH restriction in HIV+ patients	NCT04172480	Inserm-ANRS	N/A	September 2023

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 2. Current Observational Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated End Date/Interim Results
iCHIP : Effect of immune checkpoint inhibitors on HIV persistence	hivcure.com.au (no registry entry)	University of Melbourne	N/A	N/A J Immunol Methods. 2021 Dec 1;113198 AIDS. 2021 Apr 15. CROI 2020, Abstract 334
IciStem : Collaborative project to guide and investigate the potential for HIV cure in HIV+ patients requiring allogeneic stem cell transplantation for hematological disorders	IciStem website (no clinicaltrials.gov entry)	amfAR	N/A	N/A Lancet HIV. 11(6):e389-e405. IAS 2023, Abstract OALBA0504 Viruses. 2022 Sep 17;14(9):2069. CROI 2020, Abstract 339 , Abstract 348LB Lancet HIV 2020 Mar 9. HIV Persistence Workshop 2019, Abstract OP 4.5 Nature. 2019 Apr;568(7751):244-248. CROI 2019, Poster abstract 394 Ann Intern Med. 2018;169(10):674-683.
Identification and quantification of HIV CNS latency biomarkers	NCT02989285	St Vincent's Hospital, Sydney	N/A	December 2020 PNAS 119(48): e2210584119.
Immuno-virological evaluation of persons living with HIV (PLWH)	NCT05973825 (not yet open for enrollment)	University Hospital, Ghent	N/A	July 2029

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Table 2. Current Observational Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated End Date/Interim Results
Investigation of the impact of inducible, replication-competent latent HIV-1 as an impediment to HIV/AIDS cure in the context of sustained viral suppression	NCT04938518	Kenya Medical Research Institute	N/A	April 2022
LAMIVIH : Evolution of HIV reservoir, inflammation, and microbiota footprint of PLWH switching to long-acting injectable treatment	NCT05303337	Hôpital Européen Marseille	N/A	March 2024
Long-term clinical, immunologic, and virologic profiles of children who received early treatment for HIV	NCT05154513	IMPAACT	N/A	November 2027
NOVA : Netherlands cohort study on acute HIV infection	NCT05728996	Prof. Jan Prins	N/A	August 2028
Observational post-intervention controller (PIC) destination cohort	NCT05985642	AIDS Clinical Trials Group	N/A	September 2029
PediacamNEG : Negative serology in children with HIV treated early with ART	NCT06302933	Inserm-ANRS	N/A	August 2025
Post analytic treatment interruption study	NCT02761200	South East Asia Research Collaboration with Hawaii	N/A	March 2031
PRIMO (ANRS CO6): Primary infection cohort	NCT03148964	Inserm-ANRS	N/A	September 2025 See supplemental references page
Quantification of antisense HIV RNA	NCT05381844	Institut National de la Santé Et de la Recherche Médicale, France	N/A	December 2024
RESERVIH32 : Bioclinical evaluation of two biomarkers of aviremic HIV-1 in CD4 T cells of adults undergoing treatment	NCT03940521	Centre Hospitalier Universitaire de Nîmes	N/A	September 2025
Role of the IL-33/amphiregulin pathway as a potential therapeutic target in HIV infection	NCT03622177	Inserm-ANRS	N/A	September 2023 J Immunol. 2022 May 2;ji2100725.
Saturne-HIV : Sequential analysis before and after treatment initiation to unravel the role of naturally occurring extracellular vesicles in HIV infection	NCT04653610	University Hospital, Ghent	N/A	January 2027

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 2. Current Observational Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated End Date/Interim Results
TatLat: Development of a new family of HIV latency regulators (LRAs) targeting the Tat viral protein	NCT06441123 (not yet open for enrollment)	University Hospital, Montpellier	N/A	December 2025
The Gemini Study: Safety and survival of genetically modified white blood cells in HIV+ twins	NCT04799483 (closed to enrollment)	NIAID	N/A	January 2030
The Last Gift Study (for people with HIV and less than 6 months life expectancy due to terminal illness)	UCSD study website	University of California, San Diego (UCSD)	N/A	N/A Strategies for an HIV Cure 2023, Abstracts PP22 & PP73 J Virus Erad. 2023 Jun 5;9(2):100328. Curr HIV/AIDS Rep. 2022 Oct 19;1-14. J Med Ethics. 2022 Jun 22 PLoS One. 2021 May 7;16(5):e0250882. J Clin Invest. 2020 Jan 7 HIV Persistence Workshop 2019, Abstract PP 5.7.5 (see abstract book)
The role of the gastrointestinal-associated lymphoid tissue in the cure of HIV infection	NCT05652088 (enrolling by invitation)	Icahn School of Medicine at Mount Sinai	N/A	June 2025
The use of leukapheresis to support HIV pathogenesis studies	NCT01161199	University of California, San Francisco	N/A	July 2033
Thinking and memory problems in people with HIV	NCT01875588	National Institute of Neurological Disorders and Stroke (NINDS)	N/A	February 2037
TRESAX: T follicular helper reservoir in axillary lymph nodes study	hivcure.com.au (no registry entry)	Kirby Institute	N/A	N/A

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Table 3. Completed Studies

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
ADOPTIVE IMMUNOTHERAPY				
Early ART in combination with autologous HIV-specific cytotoxic T lymphocyte (CTL) infusion	NCT02231281	Yongtao Sun, MD, PhD, Tangdu Hospital, the Fourth Military Medical University	Phase III	N/A
Reconstitution of HIV-specific immunity against HIV	NCT02563509	Guangzhou 8th People's Hospital	Phase I/II	N/A
HIV-specific memory CD8 T cells adoptive immunotherapy	ChiCTR-ICR-15005775	Beijing You'an Hospital, Capital Medical University	Phase I	Front Immunol. 2019 Mar 18;10:437
HXTC : HIV 1 antigen expanded specific T cell therapy	NCT02208167	University of North Carolina, Chapel Hill	Phase I	Mol Ther. 2018 Oct 3;26(10):2496-2506.
ANALYTICAL TREATMENT INTERRUPTION				
TESOVIR : Tracking and exploring the source of viral rebound	NCT03117985	Centre Hospitalier Régional d'Orléans	N/A	Terminated (no interesting results)
ANTIBODIES				
CHERUB 001 : IVIG in primary HIV infection	No clinicaltrials.gov entry	CHERUB	N/A	HIV Med. 2017 Jul 18.
GSK3810109A (broadly neutralizing antibody formerly named N6-LS)	NCT04871113	ViiV Healthcare	Phase IIa	EACS 2023, Abstracts PS8.05 & eP.A.099 CROI 2023, Abstract 520 HIV Glasgow 2022, Abstract O34
3BNC117 (broadly neutralizing monoclonal antibody)	NCT02446847	Rockefeller University	Phase II	Nature. 2016 Jul 28; 535(7613):556–560
3BNC117	NCT02588586	Rockefeller University	Phase II	J Exp Med. 215(9):2311-2324.
UB-421 (antibody inhibitor of HIV binding to CD4 receptors)	NCT03743376	United BioPharma	Phase II	N/A
UB-421	NCT02369146	United BioPharma	Phase II	N Engl J Med. 2019;380(16):1535-45

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
ANTIBODIES (Cont.)				
vedolizumab (anti- $\alpha_4\beta_7$ integrin antibody)	NCT03577782	Hospitales Universitarios Virgen del Rocío	Phase II	CROI 2022, Abstract 359 XI Congreso Nacional GeSIDA, Abstract PO-48 (video)
VRC01 (broadly neutralizing monoclonal antibody)	NCT02664415	National Institute of Allergy and Infectious Diseases (NIAID)	Phase II	J Clin Invest. 130(6):3299-3304. Lancet HIV. 2019 May;6(5):e297-e306. IAS 2017, Abstract TUAB0106LB (slides , video)
PGT121 + VRC07-523LS +/- PGDM1400 (broadly neutralizing antibodies)	NCT03721510	International AIDS Vaccine Initiative	Phase I/IIa	CROI 2024, Abstracts 121 , 483
VRC01 (broadly neutralizing antibody) in infants	NCT03208231	NIAID	Phase I/II	AIDS 2022, Abstract OALBB0102
VRC01LS + 10-1074 (broadly neutralizing antibodies) in early-treated children	NCT03707977	NIAID	Phase I/II	Sci Transl Med. 2023 15(703):eadh0004. CROI 2023, Abstracts 141 , 828 JAIDS. 2022 Oct 1;91(2):182-188. CROI 2022, Abstract 32 CROI 2021, Abstract 609 , Webcast
ABBV-382 (anti- $\alpha_4\beta_7$ integrin antibody)	NCT04554966	AbbVie	Phase Ib	N/A
10-1074 (broadly neutralizing monoclonal antibody)	NCT02511990	Rockefeller University	Phase I	Nat Med. 2017 Feb;23(2):185-191
10-1074-LS + 3BNC117-LS (long-acting broadly neutralizing antibodies)	NCT03554408	Rockefeller University	Phase I	N/A

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
ANTIBODIES (Cont.)				
3BNC117	NCT02018510	Rockefeller University	Phase I	Nature. 2015 Jun 25;522(7557):487-91
3BNC117 + 10-1074	NCT03571204	NIAID	Phase I	Nature. 2022 Jun; 606(7913):375-381.
3BNC117 + 10-1074	NCT02825797	Rockefeller University	Phase I	Nat Med. 2020 Feb;26(2):222-227 Nature. 2018 Sep;561:479-484. Nat Med. 2018 Sep 26.
3BNC117 + 10-1074	NCT03526848	Rockefeller University	Phase I	Nature. 2022 Apr 13 CROI 2022, Abstract 361
3BNC117-LS + 10-1074-LS in viremic HIV+ individuals	NCT04250636	Rockefeller University	Phase I	CROI 2022, Abstract 140
3BNC117-LS	NCT03254277	Rockefeller University	Phase I	N/A
elipovimab (formerly GS-9722; PGT121-derived broadly neutralizing antibody)	GS-US-420-3902 Adisinsight entry	Gilead Sciences	Phase I	CROI 2022, Abstract 349 CROI 2020, Abstract 39 , Webcast
PGDM1400 +/- PGT121 +/- VRC07-523LS (broadly neutralizing antibodies)	NCT03205917	International AIDS Vaccine Initiative	Phase I	Nat Med 2022 May 12 CROI 2022, Abstract 139
PGT121	NCT02960581	International AIDS Vaccine Initiative	Phase I	Nat Med. 2021 Oct 7. CROI 2019, Abstract 145 , Webcast
SAR441236 (tri-specific broadly neutralizing antibody)	NCT03705169	NIAID	Phase I	CROI 2024, Abstract 118 Results posted in clinicaltrials.gov
vedolizumab	NCT02788175	NIAID	Phase I	Sci Transl Med. 11(509):eaax3447. AIDS 2018, WESS0102
VRC01 + 10-1074	NCT03831945	NIAID	Phase I	Terminated: unable to recruit due to COVID

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
ANTIBODIES (Cont.)				
VRC01 in acute HIV infection	NCT02591420	NIAID	Phase I	CROI 2023, Abstract 430
VRC01	NCT02411539	NIAID	Phase I	OFID. 5(10):ofy242.
VRC01	NCT02471326	NIAID	Phase I	N Engl J Med. 2016 Nov 24;375(21):2037-2050
VRC01	NCT02463227	NIAID	Phase I	CROI 2023, Abstract 390 HIV Persistence Workshop 2022, Abstract PP 4.10 (slides) N Engl J Med. 375(21):2037-2050 CROI 2016, Abstract 32LB, Webcast
VRC01	NCT01950325	NIAID	Phase I	Sci Transl Med. 7(319):319ra206
VRC01LS, VRC07-523LS (long-acting broadly neutralizing antibodies)	NCT02840474	NIAID	Phase I	IAS 2019, Abstract WEAA0305LB (video, at 45:36)
ANTI-CMV THERAPY				
Ietermovir (Prevymis)	NCT04840199	NIAID	Phase II	CROI 2024, Abstract 354
ANTI-FIBROTIC				
ACE inhibitors	NCT01535235	UCSF/amfAR	Phase IV	Pathog Immun. 2017;2(3):310-34.
losartan	NCT01852942	University of Minnesota	Phase II	CROI 2020, Abstract 277
telmisartan	NCT01928927	AIDS Clinical Trials Group	Phase II	CROI 2019, Abstract 395 J Infect Dis. 2018 217(11):1770-1781
telmisartan	NCT02170246	Yale University	Phase I	CROI 2019, Abstract 300

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
ANTI-INFLAMMATORY				
canakinumab (IL-1 β inhibitor)	NCT02272946	University of California, San Francisco	Phase II	J Am Coll Cardiol. 72(22):2809-2811. CROI 2017, Abstract 126 , Webcast
CD24Fc (human CD24 extracellular domain and human IgG1 Fc fusion protein)	NCT03960541	Oncolmmune, Inc.	Phase II	“Terminated (Business Reasons)”
High dose vitamin D supplementation	NCT03426592	University of Melbourne	Phase II	J Virus Erad. 2023 Aug 29;9(3):100345. CROI 2022, Abstract 355
Camu Camu (<i>Myrciaria dubia</i>)	NCT04058392	McGill University Health Centre	Phase I	N/A
CC-11050 (phosphodiesterase-4 inhibitor)	NCT02652546	NIAID	Phase I	OFID. 6(6):ofz246. AIDS 2018, Poster abstract LBPEB021
ANTI-PROLIFERATIVE				
mycophenolate mofetil (MMF)	NCT03262441	Fred Hutchinson Cancer Research Ctr	Phase I	OFID 2022, ofac620 CROI 2020, Abstract 340
ANTIRETROVIRAL THERAPY				
dolutegravir in reservoirs	NCT02924389	Emory University	Phase IV	AIDS. 2018 Sep 24;32(15):2151-2159.
HIV reservoir dynamics after switching to dolutegravir in patients on a PI/r based regimen	NCT02513147	Hospital Universitari Vall d'Hebron Research Institute	Phase IV	N/A
raltegravir or efavirenz + tenofovir + emtricitibine	NCT00734344	University of Alabama at Birmingham	Phase IV	N/A
doravirine concentrations and antiviral activity in cerebrospinal fluid	NCT04079452	Fundacio Lluita Contra la SIDA	Phase III	Clin Infect Dis. 2021 Sep 21;ciab835.
IDOLTIB: Impact of dolutegravir + lamivudine simplification on HIV-1 reservoirs	NCT04034862	University of Liege	Phase III	N/A
ABX464	NCT02735863	Abivax S.A.	Phase II	J. Virus Eradication 2019;5:10–22

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
ANTIRETROVIRAL THERAPY (Cont.)				
ABX464	NCT02990325	Abivax S.A.	Phase I/II	J Infect Dis. jiad251. Clin Infect Dis. 2021 Aug 26:ciab733. CROI 2020, Abstract 335 HIV Persistence Workshop 2019, Abstract OP 8.3
ANTIRETROVIRAL THERAPY IN HIV CONTROLLERS				
emtricitabine + rilpivirine + tenofovir	NCT01777997	AIDS Clinical Trials Group/NIAID	Phase IV	J Infect Dis. 2020 June 4:jiaa294 Clin Infect Dis. 2019 May 25. CROI 2019, Poster abstract 508 CROI 2018, Poster abstract 229
raltegravir + tenofovir + emtricitabine	NCT01025427	University of California, San Francisco	Phase IV	PLoS Pathog. 2013;9(10):e1003691
ASSEMBLY INHIBITORS				
BIT225	ACTRN12617000025336	Biotron Limited	Phase II	J Infect Dis. 2021 Jun 4;223(11):1914-1922. CROI 2020, Abstract 506 HIV DART 2018
BIT225	ACTRN12612000696897	Biotron Limited	Phase I	J Antimicrob Chemother. 2016 Mar;71(3):731-8
CANNABINOIDS				
GALIG-CBD: Effects of cannabidiol on the activation of autophagy and inflammation genes	NCT05306249	Centre Hospitalier Régional d'Orléans	Phase II	N/A

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
CANNABINOIDS (Cont.)				
TN-TC11M2, TN-C200M2 oral capsules	NCT03550352	McGill University Health Center	Phase II	IAS 2023, Abstract EPB0270 Cells. 12(14):1811. Biomedicines. 10(12):3168.
COMBINATIONS				
maraviroc, dolutegravir, dendritic cell vaccine, auranofin, nicotinamide	NCT02961829	Federal University of São Paulo	Not listed	CROI 2023, Abstract 383 CROI 2021, Abstract 313 AIDS Res Ther. 2022 Jan 12;19(1):2. AIDS 2020, Abstract OAXLB0105 HIV Persistence Workshop 2019, Abstract OP 8.6 Int J Antimicrob Agents. pii: S0924-8579(19)30212-2. CROI 2019, Poster abstract 399 AIDS 2018, Abstract WEPDB0105 (slides , video)
Perturbing of HIV reservoir with immune stimulation: Fluarix, Pneumovax vaccines	NCT02707692	University of California, San Diego	Not listed	AIDS. 2024 Mar 25. CROI 2022, Abstract 358
ART +/- cyclosporine A, GM-CSF, pegylated interferon-alpha2b, IL-2	NCT00979706	Juan A. Arnaiz	Phase IV	Lancet HIV. 10(1):e42-e51. AIDS 2022, Abstract OAA0205
MVA.HTI + ChAdOx1.HTI therapeutic vaccines + vesatolimod (TLR7 agonist)	NCT04364035	Aelix Therapeutics	Phase IIa	CROI 2023, Abstract 433 HIV Persistence Workshop 2022, Abstract PP 7.4

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
COMBINATIONS (Cont.)				
ROADMAP: romidepsin + 3BNC117	NCT02850016	Rockefeller University	Phase IIa	Lancet Microbe. 2022 Mar;3(3):e203-e214 CROI 2020, Abstract 38 , Webcast
TITAN: lefitolimod + 3BNC117 + 10-1074 (TLR9 agonist + broadly neutralizing antibodies)	NCT03837756	University of Aarhus	Phase IIa	Nat Med. 2023 Sep 11 CROI 2023, Abstract 136
Adoptive transfer of haploidentical natural killer cells and IL-2	NCT03346499	University of Minnesota - Clinical and Translational Science Institute	Phase II	J Infect Dis. 2024 Jan 11:jjad578
Albuvirtide (fusion inhibitor) + 3BNC117	NCT04819347	Frontier Biotechnologies Inc.	Phase II	N/A, unknown if study opened
ASC22 (anti-PD-L1 antibody) + chidamide (HDAC inhibitor)	NCT05129189	Shanghai Public Health Clinical Center	Phase II	IAS 2023 , Abstract LBEPB18
eCLEAR: romidepsin + 3BNC117	NCT03041012	Aarhus University Hospital	Phase II	CROI 2024, Abstract 486 HIV Persistence Workshop 2022, Abstract OP 1.9 (slides) Nat Med. 2022 Oct 17 CROI 2022, Abstract 62 , Abstract 122
ERAMUNE-01 (antiretroviral intensification +/- interleukin-7)	NCT01019551	ORVACS/Cytheris SA/Merck Sharp & Dohme Corp./Pfizer	Phase II	AIDS. 2016 Jan;30(2):221-30
ERAMUNE-02 (DNA/Ad5 vaccine, ART intensification)	NCT00976404	Vical/GenVec/CHERUB/NIH Vaccine Research Center/ORVACS	Phase II	Lancet HIV. 2015 Mar;2(3):e82-91 CROI 2014, Poster abstract 422
MVA HIV-B +/- vedolizumab (viral vector vaccine +/- anti- $\alpha_4\beta_7$ integrin antibody)	NCT04120415	ANRS	Phase II	Stopped due to logistical issues

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
COMBINATIONS (Cont.)				
Research in Viral Eradication of HIV Reservoirs (RIVER): ART, ChAdV63.HIVconsv & MVA.HIVconsv vaccines, vorinostat	NCT02336074	Imperial College London	Phase II	CROI 2024, Abstract 504 Sci Rep. 13(1):17155. J Virus Erad. 2021 Sep 14; 7(3):100056. Lancet. 395 (10227):888-898 AIDS 2018, Abstract TUAA0202LB (slides , video)
UB-421 + chidamide	NCT05056974	United BioPharma	Phase II	N/A
vorinostat +/- tamoxifen in postmenopausal women	NCT03382834	NIAID	Phase II	Clin Infect Dis. 2022 Feb 17:ciac136. CROI 2020, Abstract 333 , Webcast HIV Persistence Workshop 2019, Abstract OP 3.2
disulfiram + vorinostat	NCT03198559 (suspended due to neurotoxicity)	The Peter Doherty Institute for Infection and Immunity	Phase I/II	AIDS. 2021 Sep 29. CROI 2019, Abstract 401
GTU-MultiHIV B-clade + MVA HIV-B +/- vedolizumab (DNA + viral vector vaccines +/- anti- $\alpha_4\beta_7$ integrin antibody)	NCT02972450	Inserm-ANRS	Phase I/II	Terminated due to bankruptcy of FITBiotech
panobinostat + pegylated interferon-alpha2a	NCT02471430	Massachusetts General Hospital	Phase I/II	Cell. 187(5):1238-1254.e14. CROI 2022, Abstract 357 CROI 2020, Abstract 341
Vacc-4x (peptide-based therapeutic vaccine) + romidepsin	NCT02092116	Bionor Immuno AS/Celgene	Phase I/II	CROI 2023, Abstract 337 CROI 2019, Abstract 397 Lancet HIV. 2016 Oct;3(10):e463-72

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
COMBINATIONS (Cont.)				
Vacc-4x + lenalidomide	NCT01704781	Bionor Immuno AS	Phase I/II	Results posted in clinicaltrials.gov
vorinostat + hydroxychloroquine + maraviroc (VHM)	NCT02475915 NCT02470351 (CNS substudy)	South East Asia Research Collaboration with Hawaii	Phase I/II	J Virus Erad. 2020 (6) 100004 AIDS 2016, Abstract TUAX0101LB
elipovimab (formerly GS-9722) +/- vesatolimod	GS-US-420-3902 (#18 on list, no clinicaltrials.gov entry)	Gilead Sciences	Phase Ib	N/A, elipovimab discontinued (see Adis Insight)
Adoptive transfer of haploidentical NK cells and N-803	NCT03899480	University of Minnesota - Clinical and Translational Science Institute	Phase I	J Infect Dis. 2024 Jan 11:jiad578
AGS-004 + vorinostat	NCT02707900	NIAID	Phase I	Sci Rep. 10(1):5134 , IAS 2019, Poster abstract MOPEB272
CD4-ZETA gene-modified T cells +/- interleukin-2 (IL-2)	NCT01013415	University of Pennsylvania	Phase I	CROI 2020, Abstract 337 , Webcast Mol Ther. 5(6):788-97
chemotherapy + maraviroc in people with non-Hodgkin lymphoma	NCT02486510	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal	Phase I	Terminated due to futility criteria
Chidamide + CAR-T or TCR-T cell therapy	NCT03980691	Guangzhou 8th People's Hospital	Phase I	Cell Discov. 10(1):49
DCV3 (dendritic cell-based vaccine pulsed with autologous inactivated HIV) + pegylated interferon	NCT02767193	Judit Pich Martínez, Fundació Clínic per la Recerca Biomèdica	Phase I	Front Immunol. 2021 Nov 11;12:767370 , CROI 2020, Abstract 282 J Infect Dis. 2020; 221(10):1740-1742
MVA-B (viral vector vaccine) +/- disulfiram	NCT01571466	Hospital Clinic of Barcelona/HIVACAT	Phase I	PLoS One. 2015 Nov 6;10(11):e0141456 , JAC. pii: dkv046

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
COMBINATIONS (Cont.)				
MVA.HIVconsv + romidepsin	NCT02616874	IrsiCaixa	Phase I	EBioMedicine. 95:104732. CROI 2023, Abstracts 385 , 481 Microbiome. 10(1):59. EBioMedicine. 78:103956. AIDS. 2021 Nov 3 JAC. dkaa523. Front Immunol. 11:823. CROI 2019, Abstract 438 CROI 2017, Abstract 119LB , Webcast
peginterferon alfa-2b + 3BNC117 + 10-1074 (BEAT-2)	NCT03588715	Wistar Institute	Phase I	CROI 2024, Abstracts 179 , 511 , 1091 , 1106 HIV Res Clin Pract. 24(1):2267825. CROI 2023, Abstracts 319 , 326 , 384 , 431 HIV Persistence Workshop 2022, Abstracts PP 7.2, 8.10 CROI 2022, Abstract 352
vorinostat + HXTC: HIV 1 antigen expanded specific T cell therapy	NCT03212989	Julia Sung, MD, University of North Carolina, Chapel Hill	Phase I	J Infect Dis. jiad423. IAS 2023, Abstract TUPEA02
VRC07-523LS + vorinostat	NCT03803605	University of North Carolina, Chapel Hill	Phase I	J Infect Dis. jia487. IAS 2021, Abstract OALA01LB03 (video)
CYTOKINES				
interleukin-2 (IL-2)	NCT03308786	Case Western Reserve University	Phase II	HIV Persistence Workshop 2022, Abstract OP 8.2 (slides)

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
CYTOKINES (Cont.)				
Effect of N-803 on B cell follicles	NCT04808908	University of Minnesota	Phase I	N/A
N-803	NCT02191098	University of Minnesota - Clinical and Translational Science Institute	Phase I	Nat Med. 2022 Jan 31. CROI 2018, Poster abstract 356
DUAL-AFFINITY RE-TARGETING (DART) MOLECULES				
MGD014	NCT03570918	MacroGenics	Phase I	AIDS 2022, Abstract OAA0403 Results posted in clinicaltrials.gov
GENE THERAPIES				
OZ1	NCT00074997	Janssen-Cilag Pty Ltd	Phase II	Nat Med. 2009 Mar; 15(3): 285–292.
Cal-1 : Dual anti-HIV gene transfer construct	NCT01734850	Calimmune	Phase I/II	Results posted in clinicaltrials.gov
SB-728mR-T (autologous CD4 T cells genetically modified at the CCR5 gene) + cyclophosphamide	NCT02225665	Sangamo BioSciences	Phase I/II	N/A
SB-728-T + cyclophosphamide	NCT01543152	Sangamo BioSciences	Phase I/II	CROI 2023, Abstract 182 bioRxiv 2021.02.28 CROI 2016, Poster abstract 358LB CROI 2015, Poster abstract 434 CROI 2014, Abstract 141, Webcast
SB-728-T	NCT01252641	Sangamo BioSciences	Phase I/II	N/A
SB-728-T	NCT03666871	Case Western Reserve University	Phase I/II	N/A
VRX496 (gene-modified autologous CD4 T cells)	NCT00295477	University of Pennsylvania	Phase I/II	Blood. 2013 Feb 28; 121(9): 1524–1533
AGT103-T (gene-modified HIV-specific CD4 T cells)	NCT04561258	American Gene Technologies International Inc.	Phase I	Front Med 2022 9:1044713.
C34-CXCR4 (autologous CD4 T cells gene-modified to express HIV-inhibiting C34 peptide)	NCT03020524	University of Pennsylvania	Phase I	N/A

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
GENE THERAPIES (Cont.)				
HGTV43	No clinicaltrials.gov entry	Enzo Biochem	Phase I	AIDS 2006, Abstract MOPDA06
Long-term follow-up of HIV+ participants exposed to SB-728-T or SB-728mR-T	NCT04201782	Sangamo Therapeutics	Phase I	No significant safety issues
MazF-T (redirected MazF-CD4 autologous T cells)	NCT01787994	Takara Bio/University of Pennsylvania	Phase I	Mol Ther 2020 Nov 10 CROI 2015, Poster abstract 402
Redirected high affinity Gag-specific T cells	NCT00991224	University of Pennsylvania/Adaptimmune	Phase I	Study closed (safety): Mol Ther. 2015 Jul; 23(7): 1149–1159.
SB-728mR-T + cyclophosphamide	NCT02388594	University of Pennsylvania	Phase I	J Clin Invest. 2021. CROI 2019, Abstract 25 , Webcast
SB-728-T	NCT01044654	Sangamo BioSciences	Phase I	CROI 2023, Abstract 182 bioRxiv 2021.02.28 ICAAC 2014, Abstract H-643; ICAAC 2013, Abstract H-1464c
SB-728-T	NCT00842634	Sangamo Biosciences/University of Pennsylvania	Phase I	N Engl J Med. 2014 Mar 6;370(10):901–10
shRNA-modified CD34+ cells	NCT03517631	Shanghai Public Health Clinical Center	Phase I	N/A
TCTIWHI: Third-generation CAR-T-cell therapy	NCT04863066	Beijing 302 Hospital	Phase I	N/A
GENE THERAPIES FOR HIV-POSITIVE PEOPLE WITH CANCERS				
CRISPR CCR5 modified CD34+ cells	NCT03164135	307 Hospital of PLA (Affiliated Hospital of Academy to Military Medical Sciences)	Not listed	N Engl J Med. 2019 Sep 11
Stem cells gene-modified with M87o vector encoding HIV-inhibiting C46 peptide	NCT00858793	Universitätsklinikum Hamburg-Eppendorf	Phase I/II	N/A
Stem cells gene-modified with Cal-1	NCT03593187	Assistance Publique - Hôpitaux de Paris	Phase I/II	Mol Ther Methods Clin Dev. 2019;13:303-309
Stem cells gene-modified to encode multiple anti-HIV RNAs (rHIV7-shI-TAR-CCR5RZ)	NCT00569985	City of Hope Medical Center	Phase I	Sci Transl Med. 2010 Jun 16; 2(36): 36ra43.
GONADOTROPIN-RELEASING HORMONE (GnRH) AGONISTS				
triptorelin acetate depot	NCT03536234	Immune System Regulation AB	Phase II	N/A

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/ Presented Data
HORMONES				
somatotropin (human growth hormone)	NCT03091374	McGill University Health Center	Phase II	CROI 2021, Abstract 298 , Webcast
IMAGING STUDIES				
123I radiolabeled 3BNC117	NCT03468582	University of Lausanne Hospitals	Phase I	N/A
Radiolabeled 3BNC117 + Copper-64 radio isotope followed by MRI/PET scanning to detect HIV in vivo	NCT03063788	Bayside Health	Phase I	EBioMedicine. 2021 Feb 25;65:103252. AIDS 2020, Abstract PEA0060
IMMUNE CHECKPOINT INHIBITORS				
durvalumab (anti-PD-L1 antibody) in solid tumors	NCT03094286	Spanish Lung Cancer Group	Phase II	ESMO 2020, Abstract 1275P JAMA Oncol. 2020 Jul 1;6(7):1063-1067
cemiplimab (anti-PD-1 antibody)	NCT03787095	NIAID	Phase I/II	OFID 11(3):ofad694. JAIDS. 87(5):e234-e236. 2020 Community HIV Cure Research Workshop (slides , video) ACTG announcement
budigalimab (anti-PD-1 antibody)	NCT04223804	AbbVie	Phase Ib	CROI 2024, Abstract 106 EACS 2023, Abstract PS10.O3
BMS-936559 (anti-PD-L1 antibody)	NCT02028403	National Institute of Allergy and Infectious Diseases (NIAID)	Phase I	J Infect Dis. 2017 Jun 1;215(11):1725-1733 CROI 2016, Abstract 25 , Webcast
budigalimab (anti-PD-1 antibody)	NCT04799353	AbbVie	Phase I	EACS 2023, Abstract PS10.O3
ipilimumab (anti-CTLA-4 antibody)	NCT03407105	Medarex	Phase I	PLoS One. 2018 Jun 7;13(6):e0198158
pembrolizumab (anti-PD-1 antibody) single dose	NCT03239899	National Institute of Neurological Disorders and Stroke (NINDS)	Phase I	HIV Persistence Workshop 2022, Abstract OP 1.10 (slides)

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
IRON CHELATORS				
deferiprone	NCT02456558	ApoPharma	Phase I	N/A
JANUS KINASE INHIBITORS				
ruxolitinib	NCT02475655	NIAID	Phase II	CROI 2024, Abstract 521 IAS 2023, Abstract TUPEB15 J Clin Pharmacol. 2021 Jun 24. Clin Infect Dis. 2021 CROI 2019, Abstract 37
LATENCY-REVERSING AGENTS				
disulfiram (acetaldehyde dehydrogenase inhibitor)	NCT01286259	University of California, San Francisco/ Johns Hopkins University/amfAR	Not specified	Clin Infect Dis. 2014 58 (6): 883–90
Chidamide	NCT02902185	Tang-Du Hospital	Phase II/III	N/A
vorinostat (HDAC inhibitor)	NCT01365065	Bayside Health/Merck	Phase II	PLoS Pathog. 2014;10(10):e1004473
valproic acid (HDAC inhibitor)	NCT00289952	McGill University	Phase II	HIV Med. 2012 May;13(5):291–6
valproic acid	NCT00614458	University of North Carolina at Chapel Hill/NIAID/Abbott/Merck Sharp & Dohme	Phase II	PLoS One. 2010 5(2): e9390
Chidamide (HDAC inhibitor)	NCT02513901	Tang-Du Hospital	Phase I/II	HIV Med. 2020 Dec;21(11):747-757. AIDS 2018, Abstract WEAA0101 (slides , video)
disulfiram	NCT01944371	University of California, San Francisco/Monash University/amfAR	Phase I/II	CROI 2015, Poster abstract 428LB
panobinostat (HDAC inhibitor)	NCT01680094	University of Aarhus/Massachusetts General Hospital/Monash University/Karolinska Institutet/Novartis/amfAR	Phase I/II	CROI 2015, Abstract 109 , Webcast The Lancet HIV. 2014 Oct; 1(1): e13–e21

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/ Presented Data
LATENCY-REVERSING AGENTS (Cont.)				
romidepsin (HDAC inhibitor)	NCT01933594	AIDS Clinical Trials Group/NIAID/Gilead	Phase I/II	JID, jiaa777 CROI 2019, Abstract 26, Webcast CROI 2018, Abstract 72, Webcast
valproic acid + pyrimethamine	NCT03525730	Erasmus Medical Center	Phase I/II	Sci Adv. 2023 Mar 17;9(11):eade6675.
vorinostat	NCT01319383	University of North Carolina at Chapel Hill/NIAID/Merck.	Phase I/II	J Clin Invest. 2017 Aug 1;127(8):3126-3135. J Infect Dis. 2014 Sep 1;210(5):728-35 Nature. 487(7408):482-5
bryostatatin 1 (PKC agonist)	NCT02269605	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal	Phase I	AIDS. 2016 Jun 1;30(9):1385-92.
Euphorbia kansui	NCT04503928	Shanghai Public Health Clinical Center	Phase I	N/A, unknown if study opened
Kansui (traditional Chinese medicine with ingenols)	NCT02531295	UCSF	Phase I	Study terminated
mTOR INHIBITORS				
Impact of Everolimus on HIV persistence post kidney or liver transplant	NCT02429869	UCSF	Phase IV	Am J Transplant. 2020 Aug 11
metformin	NCT04500678	University of Hawaii	Phase II/III	AIDS Res Hum Retroviruses. 2021 Jan;37(1):24-33.
Sirolimus	NCT02440789	ACTG	Phase I/II	CROI 2019, Abstract 131, Webcast
metformin	NCT02659306	McGill University Health Center	Phase I	EBioMedicine 65:103270 CROI 2020, Poster abstract 229 CROI 2019, Poster abstract 301
OBSERVATIONAL STUDIES				
2000HIV: 2000 HIV human functional genomics partnership program	NCT03994835	Radboud University	N/A	CROI 2024, Abstracts 319, 442, 515 Front Immunol. 2022 Dec 20;13:982746

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/ Presented Data
OBSERVATIONAL STUDIES (Cont.)				
2000HIVTrained: 2000 HIV trained innate immunity in HIV elite controllers	NCT04968717	Radboud University	N/A	CROI 2024, Abstract 442 CROI 2023, Abstracts 313, 314
ACTG A5321: Decay of HIV-1 reservoirs in subjects on long-term antiretroviral therapy: The ACTG HIV reservoirs cohort (AHRC) study	N/A	AIDS Clinical Trials Group	N/A	CROI 2023, Abstracts 392, 398 J Infect Dis. 2023 Feb 10:jjad039. HIV Persistence Workshop 2022, Abstract PP 7.8 AIDS. 2022 Jun 23. Front Cell Infect Microbiol. 12:757846. J Infect Dis. 2022:jjac030 CROI 2021, Abstract 241, Webcast HIV Persistence 2019, Abstracts OP 4.6, 5.6 & PP 4.4 (see abstract book) JAIDS. 2019 Aug 15;81(5):594-599. CROI 2018, Abstract 119, Webcast Abstract 403LB PLoS Pathog. 2017 Sep;13(9):e1006629. PLoS Pathog. 2017 Apr; 13(4): e1006285
ANRS CO24 OncoVIHAC: Immune checkpoint inhibitors in HIV+ individuals with cancers	NCT03354936	Inserm-ANRS	N/A	Cells. 2022 Mar 17;11(6):1015. AIDS 2020, Abstract OAB0203
ANRS EP 44: Residual replication of HIV-1 in the gut associated lymphoid tissue (GALT)	NCT01038401	Inserm-ANRS	N/A	N/A
ANRS EP63: A chronological study of the formation of HIV cellular reservoirs through the expression of surface markers on CD4+ T cell, inc. CD32a	NCT03298360	Inserm-ANRS	N/A	N/A

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
OBSERVATIONAL STUDIES (Cont.)				
APACHE: Monitored antiretroviral pause in chronically infected HIV+ individuals with long-lasting suppressed viremia	NCT03198325	Ospedale San Raffaele	N/A	PLoS One. 2022 Mar 15;17(3):e0265348. Viruses. 2021 Jul 19;13(7):1403. AIDS: May 14, 2021 J Antimicrob Chemother. 2021 Mar 7:dkab060. J Antimicrob Chemother. 2020 Jun 15:dkaa231. HIV Persistence 2019, Abstract PP 5.7.10 J Antimicrob Chemother. 2019 April 23. pii: dkz138
ATN 147	ATN Cares website	The Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN)	N/A	CROI 2023, Abstract 457
AVIR: Characterization of HIV-1 reservoirs in adolescents with non-B HIV-1 on ART in Cameroon	NCT06363500	Chantal Biya International Reference Centre for Research on Prevention and Management of HIV/AIDS	N/A	J Virus Erad. 10(1):100367.
Biomarkers to predict time to plasma HIV RNA rebound (ACTG A5345)	NCT03001128	AIDS Clinical Trials Group	N/A	JCI Insight.9(3):e173864 CROI 2023, Abstracts 337 , 380 HIV Persistence Workshop 2022, Abstracts OP 7.3, PP 7.9 (slides) ARHR. 38(6):510-517 CROI 2022, Abstract 379 Clin Infect Dis. 2021 Jun 12;ciab541. CROI 2021, Abstract 311 , Webcast AIDS 2020, Abstract PDB0102

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
OBSERVATIONAL STUDIES (Cont.)				
CHERUB 003 (prospective HIV chemotherapy cohort study)	NCT01902693	Imperial College London/CHERUB	N/A	N/A
CLEAC : Comparison of late versus early antiretroviral therapy in children with HIV	NCT02674867	Inserm-ANRS	N/A	Front Immunol. 2021 Apr 22;12:662894. Clin Infect Dis. ciaa1931 AIDS 2018, Abstract WEAB0208LB (slides)
DOLUVOIR : Cartography of virologic reservoir related to antiretroviral concentrations in HIV-1+ patients on first line treatment containing dolutegravir	NCT04133012	Inserm-ANRS	N/A	N/A
EARTH : Early antiretroviral treatment in children with HIV	NCT05784584	PENTA Foundation	N/A	eClinicalMedicine, May 23, 2024
Effects of dolutegravir based regimen on HIV-1 reservoir and immune activation	NCT02557997	University Hospital, Strasbourg, France	N/A	J Antimicrob Chemother. 2017 Dec 13.
EPIC4 : Early Pediatric Initiation: Canada Child cure Cohort Study	CTN S 281	Canadian Institutes of Health Research (CIHR)/Canadian Foundation for AIDS Research (CANFAR)/International AIDS Society (IAS)	N/A	AIDS. 34(5):687-697 Clin Infect Dis. 2019 Mar 28. pii: ciz251 AIDS 2014, Abstract TUAB0206LB (video) Clin Infect Dis. (2014) 59 (7): 1012-1019.
EURECA : Exploratory study of cellular reservoirs in blood	NCT02858414	Centre Hospitalier Universitaire de Besancon	N/A	Viruses. 2018 Apr 13;10(4).
Expectation, motivation, and experience of HIV+ patients regarding participation to an HIV cure-related clinical trial (AMEP-EHVA T02)	NCT05280392	ANRS	N/A	Abstract , AIDS Impact 2023
FXReservoir : Study of the effects of farnesoid X receptor ligands on reactivation of latent provirus	NCT03618862	Hospices Civils de Lyon	N/A	N/A
Genotyping FcγRs genes	NCT03130296	University Hospital, Strasbourg, France	N/A	Genes Immun. 2020 Aug;21(4):263-268
HCURE : Impact of HCV DAAs on antiviral immunity & HIV reservoir in HIV-HCV coinfection	NCT03244371	Assistance Publique Hopitaux De Marseille	N/A	N/A

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
OBSERVATIONAL STUDIES (Cont.)				
HEATHER: HIV reservoir targeting with early antiretroviral therapy	UK CPMS17589	University of Oxford/Medical Research Council/British HIV Association	N/A	Front Immunol. 2024 Mar 18:15:1352123. Front Immunol. 2021; 12: 647688. J Infect Dis. 2019 Nov 28. pii: jiz563 Mucosal Immunol. 2019 Sep;12(5):1212-1219.
HIV-PRADA: HIV persistence in lymph node and peripheral blood	NCT03426189	University of Melbourne	N/A	Cell Rep Med. 2022 Sep 28:100766 CROI 2021, Abstract 301 , Webcast
HIV resistance and treatment strategies	NCT00581802	NIAID	N/A	N/A
HIV-STAR: HIV sequencing after treatment interruption to identify the clinically relevant anatomical reservoir	NCT02641756	University Hospital, Ghent	N/A	Cell Rep. 39(4):110739. IAS 2021, Abstract PEA036 (poster, video) J Virus Erad. 2021 Jan 23;7(1):100029. CROI 2020, Abstract 324 Cell Host Microbe. 2019 Sep 11;26(3):347-358.e7. AIDS 2018, Abstract WEAA0201 (slides, video), poster abstract THPEB096
Host & viral factors associated with HIV elite control	UK CPMS16146	University College London Hospitals NHS Foundation Trust	N/A	N/A
HSCT-HIV: Allogeneic hematopoietic stem cell transplantation in HIV+ patients	NCT02732457	Kirby Institute	N/A	Terminated by Protocol Steering Committee
ImmunoCo27: Co-adaptation between HIV and CD8 cellular immunity	NCT02886416	Inserm-ANRS	N/A	N/A
IMPAACT 2015: Evaluation of the HIV-1 reservoir in the CNS of perinatally-infected youth and young adults with cognitive impairment	NCT03416790	IMPAACT	N/A	AIDS. 2024 May 29.
Impact of ART adherence on HIV persistence and inflammation	NCT02797093	University of Colorado, Denver	N/A	N/A

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
OBSERVATIONAL STUDIES (Cont.)				
Impact of a short-term ATI and re-initiation of antiretroviral therapy on immunologic and virologic parameters in HIV+ individuals	NCT03225118	NIAID	N/A	J Infect Dis. 2020 May 22;jiaa270.
In vitro autologous vaccine development to activate HIV reservoirs	UK CPMS17532	Imperial College London/amfAR	N/A	N/A
ISALA: Analytical treatment interruption	NCT02590354	Institute of Tropical Medicine, Belgium	N/A	Strategies for an HIV Cure 2023, Abstract PP20 IAS 2023, Abstract TUPEA07 J Int AIDS Soc. 2020 Feb;23(2):e25453. CROI 2019, Poster abstract 389, Webcast
Long-term effects of ART in acute HIV infection	ChiCTR1800015006	Key Laboratory of AIDS Immunology of National Health and Family Planning Commission, The First Affiliated Hospital, China Medical University	N/A	N/A
LoViReT: Low viral reservoir treated patients	NCT02972931	IrsiCaixa	N/A	HIV Persistence Workshop 2022, Abstract PP 3.13 J Intern Med. 2022 Mar 28. EBioMedicine. 2020 Jun 21;57:102830. CROI 2020, Abstract 374 HIV Persistence Workshop 2019, Abstract OP 3.5 (see abstract book) HIV Persistence Workshop 2017, Abstract OP 8.6
Measurement for viral reservoir and immune function in HIV-1+ patients under antiretroviral therapy	NCT04068441	National Taiwan University Hospital	N/A	JAIDS. 2021 Apr 1;86(4):500-508
MUCOVIR: Exploration of HIV reservoirs	NCT01019044	Objectif Recherche Vaccins SIDA	N/A	JAIDS. 2013 Mar 1;62(3):255-9

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
OBSERVATIONAL STUDIES (Cont.)				
PembroHIV: Treatment with immunological checkpoint inhibitors of HIV+ individuals with cancer	NCT03767465	IrsiCaixa	N/A	HIV Persistence Workshop 2019, Abstract PP 4.2 (see abstract book)
PITCH: Prospective interruption of therapy towards a cure for HIV pilot study	NHS Health Research Authority approval (not entered into any online registry)	University of Oxford	N/A	CROI 2022, Abstract 266 BHIVA Digital Conference, Nov 22–24, 2020, Abstract P22
Quantitative measurement and correlates of the latent HIV reservoir in virally suppressed Ugandans	NCT02154035	NIAID	N/A	EBioMedicine. 105040. Virus Evol. 2023 Jul 27;9(2):vead046. JCI Insight. 2020 Jun 16;139287. CROI 2020, Abstract 385 Persistence Workshop 2019, Abstract OP 7.4 Clin Infect Dis. 2017 Oct 15;65(8):1308-1315.
Role of anti-Tat immunity on disease progression in HIV+ asymptomatic adults	NCT01029548	National HIV/AIDS Research Center (CNAIDS), Istituto Superiore di Sanità, Rome, Italy	N/A	Retrovirology. 2014 Jun 24;11:49.
Role of anti-Tat immunity on disease progression in HIV+ cART-treated adults	NCT01024556	CNAIDS, Istituto Superiore di Sanità, Rome, Italy	N/A	EBioMedicine 00 (2021) 103306
Seroprevalence of anti-Tat antibodies in South African people with HIV	NCT01359800	CNAIDS, Istituto Superiore di Sanità, Rome, Italy	N/A	N/A
Size of the HIV-1 reservoir and ongoing replication in defined cohorts	UK CPMS16004	University College London/amfAR	N/A	N/A
Specimen repository for HIV immunopathogenesis	NCT03579381	AIDS Healthcare Foundation	N/A	N/A
Tissue drug levels of HIV medications	NCT01490346	University of Minnesota – Clinical and Translational Science Institute/NIAID	N/A	Proc Natl Acad Sci USA. 2014 Feb 11;111(6):2307-12.
ULTRASTOP (Towards HIV Functional Cure) ERAMUNE-03 (antiretroviral treatment interruption)	NCT01876862	Objectif Recherche VACcin Sida (ORVACS)/Fondation Bettencourt Schueller	N/A	AIDS, Published Ahead-of-Print, January 4, 2016
VIRECT: Impact of pre-ART CD4 T cell level on the rectal reservoir in long-term HIV-1 treated men	NCT02526940	Centre Hospitalier Universitaire de Saint Etienne	N/A	N/A

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
PROTEASOME INHIBITORS				
ixazomib	NCT02946047	Mayo Clinic	Phase I	EClinicalMedicine 42:101225.
STEM CELL TRANSPLANTATION				
HIVECT: HIV eradication through cord-blood transplantation	NCT02923076	Puerta de Hierro University Hospital	N/A	N/A
IMPAACT P1107: Cord blood transplantation using CCR5-Δ32 donor cells for the treatment of HIV and underlying disease	NCT02140944	International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT)	N/A	Cell. 2023 Mar 16;186(6):1115-1126.e8. CROI 2022, Abstract 65 ASH 2018, Abstract 2184
Cord blood transplant with OTS for the treatment of HIV+ hematologic cancers	NCT04083170	Fred Hutchinson Cancer Research Center	Phase II	Study stopped due to end of funding and lack of accrual
BMT CTN 0903: Allogeneic transplant in individuals with chemotherapy-sensitive hematologic malignancies and coincident HIV infection	NCT01410344	National Heart, Lung, & Blood Institute/National Cancer Institute/Blood & Marrow Transplant Clinical Trials Network	Phase II	Biol Blood Marrow Transplant. 2019 Jul 4. pii: S1083-8791(19)30417-3. J Clin Oncol. 35, no. 15 suppl (May 2017) 7006-7006.
HLA-mismatched unrelated donor bone marrow transplantation	NCT02793544	Center for International Blood and Marrow Transplant Research	Phase II	HRSA Advisory Council on Blood Stem Cell Transplantation, September 25, 2020
Immune response after stem cell transplant in HIV-positive patients with hematologic cancer	NCT00968630	Fred Hutchinson Cancer Research Center	Phase II	N/A
Optimized antiretroviral therapy during allogeneic hematopoietic stem cell transplantation in HIV-1 individuals	NCT01836068	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase I	JAIDS 2021 Nov 8. AIDS Res Hum Retroviruses. 2021 Jun 9. Lancet HIV. 2020 Jul 7: S2352-3018(20)30073-4.

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
STIMULANTS				
EMRLHD: Effect of methamphetamine on residual latent HIV disease study	NCT03825536	University of California, San Francisco	Phase IV	N/A
T-CELL RECEPTOR-BASED BISPECIFICS				
IMC-M113V in HLA-A*02:01 positive people	IMC-M113V-101	Immunocore	Phase I/II	CROI 2023, Abstract 436
THERAPEUTIC VACCINES				
AGS-004 (personalized therapeutic vaccine utilizing patient-derived dendritic cells and HIV antigens)	NCT00672191	Argos Therapeutics	Phase IIb	JAIDS. 2016 May 1;72(1):31-8
AGS-004	NCT01069809	Argos Therapeutics	Phase IIb	ARHR. 34(1):111-122 CROI 2014, Poster abstract 344
iHIVARNA-01 (TriMix & HIV antigen naked messenger RNA)	NCT02888756	Rob Gruters, Erasmus Medical Center	Phase IIa	Vaccines (Basel). 2019 Dec 6;7(4). pii: E209.
DermaVir (topically applied DNA vaccine)	NCT00711230	Genetic Immunity	Phase II	N/A
DermaVir	NCT00918840	Genetic Immunity	Phase II	N/A
GSK Biologicals HIV Vaccine 732462 (p24-RT-Nef-p17 fusion protein vaccine)	NCT01218113	GlaxoSmithKline	Phase II	Medicine (Baltimore). 2016 Feb;95(6):e2673
GTU-multiHIV + LIPO-5 (DNA + lipopeptide vaccines)	NCT01492985	Inserm-ANRS	Phase II	J Virol. 2021 May; 95(9): e02165-20. J Infect Dis. 2019 Jul 2;220:S5-S6 AIDS. 2018 Oct 15 HIVR4P 2016, Abstract P27.09
Tat protein vaccine	NCT01513135 NCT02712489 (extended follow-up study)	CNAIDS, Istituto Superiore di Sanità, Rome, Italy	Phase II	Retrovirology. 2016 Jun 9;13(1):34
Tat protein vaccine	NCT00751595 NCT02118168 (extended follow-up study)	Barbara Ensoli, MD, Istituto Superiore di Sanità	Phase II	Front. Immunol. February 13, 2019 Retrovirology. 2015 Apr 29;12(1):33 PLoS One. 2010 Nov 11;5(11):e13540

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
THERAPEUTIC VACCINES (Cont.)				
Vacc-4x (peptide-based vaccine)	NCT01712256	Bionor Immuno AS	Phase II	PLoS One. 2019 Jan 30;14(1):e0210965.
Vacc-4x	NCT00659789	Bionor Immuno AS	Phase II	Lancet Infect Dis. 2014 Apr;14(4):291-300
VAC-3S (peptide-based vaccine)	NCT02041247	InnaVirVax	Phase II	NPJ Vaccines (2019) 4:1 IAS 2017, Abstract MOSY0404 (slides , video)
VAC-3S	NCT02390466	InnaVirVax	Phase I/IIa	N/A
VAC-3S (peptide-based vaccine)	NCT01549119	InnaVirVax	Phase I/IIa	30 Years of HIV Science, 2013, Poster abstract 145
AGS-004	NCT02042248	University of North Carolina at Chapel Hill/Argos Therapeutics/U.S. National Institutes of Health (NIH)	Phase I/II	N/A
Autologous HIV-1 ApB DC Vaccine	NCT00510497	Sharon Riddler, University of Pittsburgh/NIAID	Phase I/II	J Infect Dis. 2016 May 1;213(9):1400-9
Dendritic cells pulsed with chemically inactivated HIV	NCT02766049	University of Sao Paulo General Hospital	Phase I/II	J. Cellular Immunotherapy xx (2016) 1-10 J Int AIDS Soc. 2014 Jan 10;17:18938
Dendritic cell vaccine	NCT00833781	Massachusetts General Hospital	Phase I/II	JAIDS 71(3):246-53.
Dendritic cell vaccine (DCV-2)	NCT00402142	Hospital Clinic of Barcelona	Phase I/II	Sci Transl Med. 2013 Jan 2;5(166):166ra2
DermaVir	NCT00270205	AIDS Clinical Trials Group	Phase I/II	JAIDS. 2013 Dec 1;64(4):351-9
GTU®-MultiHIV B clade vaccine	NCT02457689	Imperial College London	Phase I/II	Front Immunol. 2019 Dec 13;10:2911.
p24CE1/2 + p55 ^{gag} conserved-element DNA vaccines	NCT03560258	NIAID	Phase I/II	AIDS. 2023 Dec 4.

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
THERAPEUTIC VACCINES (Cont.)				
PENNVAX-GP or INO-6145 + IL-12 DNA adjuvant (INO-9012) (DNA vaccines)	NCT03606213	Steven Deeks, UCSF	Phase I/II	CROI 2023, Abstracts 408 , 428 HIV Persistence Workshop 2022, Abstract PP 8.3 CROI 2022, Abstract 284
Tat Oyi (protein-based vaccine)	NCT01793818	Biosantech	Phase I/II	Retrovirology. 2016 Apr 1;13:21
THV01 (lentiviral vector-based therapeutic vaccine)	NCT02054286	Theravectys S.A.	Phase I/II	N/A
TUTI-16 (synthetic HIV-1 Tat epitope vaccine)	NCT01335191	Thymon, LLC	Phase I/II	Hum Vaccin Immunother. 2012 Oct;8(10):1425-30
Vacc-C5 (peptide-based vaccine)	NCT01627678	Bionor Immuno AS	Phase I/II	JAIDS April 2018;77:57 BMC Infect Dis. 2017 Mar 24;17(1):228
Ad26.Mos4.HIV + MVA-Mosaic or clade C gp140 + mosaic gp140 (viral vector vaccines + proteins)	NCT03307915	Janssen Vaccines & Prevention B.V.	Phase I	NPJ Vaccines. 9(1):89.
Ad26.Mos.HIV + MVA-Mosaic	NCT02919306	Janssen Vaccines & Prevention B.V.	Phase I	Cell Rep. 43(6):114344. HIV Persistence Workshop 2022, Abstract PP 8.6 Nat Med March 23, 2020.
AFO-18 (peptide-based vaccine)	NCT01141205	Statens Serum Institut (SSI)/Ministry of the Interior and Health, Denmark/European and Developing Countries Clinical Trials Partnership (EDCTP)	Phase I	AIDS Res Hum Retroviruses. 2013 Nov;29(11):1504-12
AFO-18 (peptide-based vaccine)	NCT01009762	SSI/Rigshospitalet/Hvidovre University Hosp./Ministry of Interior & Health, Denmark	Phase I	Clin Immunol. 2013 Feb;146(2):120-30
AT20-KLH	MED-AT20-001	Medestea Research & Production SpA, Turin	Phase I	Vaccine. 2014 Feb 19;32(9):1072-8

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
THERAPEUTIC VACCINES (Cont.)				
ChAdOx1.HTI, MVA.HTI, ConM SOSIP.v7 gp140	NCT05208125	IrsiCaixa	Phase I	N/A
ChAdV63.HIVconsv + MVA.HIVconsv (viral vector vaccines)	NCT01712425	IrsiCaixa/Fundació Lluita contra la SIDA/Hospital Clinic of Barcelona/ HIVACAT/University of Oxford	Phase I	EClinicalMedicine. 2019 Jun 5;11:65-80. IAS 2015, Poster abstract MOPEA036
Dendritic cells loaded with HIV-1 lipopeptides	NCT00796770	Baylor Research Institute/ANRS	Phase I	PLoS Pathog. 2019 15(9):e1008011. Eur J Immunol. 2014 Sep;44(9):2802-10. Retrovirology 2012, 9(Suppl 2):P328
DermaVir	NCT00712530	Genetic Immunity	Phase I	PLoS One. 2012 7(5): e35416
D-GPE DNA + M-GPE MVA (DNA + viral vector vaccines)	NCT01881581	Centers for Disease Control and Prevention, China	Phase I	N/A
DNA.HTI + MVA.HTI + ChAdOx1.HTI (DNA + viral vector vaccines) (ATI extension)	NCT04385875	Fundacio Lluita Contra la SIDA	Phase I	N/A
DNA.HTI + MVA.HTI + ChAdOx1.HTI (DNA + viral vector vaccines)	NCT03204617	Aelix Therapeutics	Phase I	HIV Persistence Workshop 2022, Abstract OP 8.3 (slides) Nat Med. 2022 Oct 27. CROI 2021, Abstract 161, Webcast
HIVAX (lentiviral vector-based therapeutic vaccine)	NCT01428596	GeneCure Biotechnologies	Phase I	Vaccine. 2020;S0264-410X(20)30485-0 Vaccine. 2016;34(19):2225-32
HIV-v (peptide-based vaccine)	NCT01071031	PepTcell Limited	Phase I	Vaccine. 2013 Nov 19;31(48):5680-6
iHIVARNA-01 (TriMix & HIV antigen naked messenger RNA)	NCT02413645	Biomedical Research Institute August Pi i Sunyer (IDIBAPS)	Phase I	AIDS. 2018 Nov 13;32(17):2533-2545.
JS7 DNA + MVA62B (DNA + viral vector vaccines)	NCT01378156	GeoVax, Inc.	Phase I	PLoS One. 2016 Oct 6;11(10):e0163164

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
THERAPEUTIC VACCINES (Cont.)				
MAG pDNA vaccine +/- IL-12	NCT01266616	NIAID	Phase I	JAIDS. 2016 Feb 1;71(2):163-71.
MAG-pDNA + rVSV _{IN} HIV-1 Gag (DNA + viral vector vaccines)	NCT01859325	NIAID/Profectus Biosciences, Inc.	Phase I	J. Virology May 20, 2020 CROI 2019, Poster abstract 392 Sci Transl Med. 2017 Dec 6;9(419). pii: eaan8848
MVA.HIVconsv	NCT01024842	University of Oxford/Medical Research Council	Phase I	J Int AIDS Soc. 2017 May 19;20(1):21171.
MVA.tHIVconsv3 +/- MVA.tHIVconsv4 (viral vectors)	NCT03844386	University of North Carolina, Chapel Hill	Phase I	Results posted in clinicaltrials.gov
PENNVAX-B (Gag, Pol, Env) + electroporation	NCT01082692	Inovio Pharmaceuticals	Phase I	Retrovirology 2012, 9(Suppl 2):P276
PENNVAX-B +/- IL-12 or IL-15	NCT00775424	University of Pennsylvania	Phase I	N/A
Recombinant adenovirus type 5 vaccine	NCT02762045	China CDC	Phase I	N/A
rMVA-HIV + rFPV-HIV (viral vector vaccines) in young adults	NCT00107549	NIAID	Phase I	AIDS. 2011 Nov 28; 25(18): 2227-2234
Tat protein vaccine	NCT00505401 NCT01024595 (extended follow-up study)	CNAIDS, Istituto Superiore di Sanità, Rome, Italy	Phase I	Rev Recent Clin Trials. 2009 Sep;4(3):195-204 Vaccine. 2009 May 26;27(25-26):3306-12 AIDS. 2008 Oct 18;22(16):2207-9
TOLL-LIKE RECEPTOR AGONISTS				
MGN1703 toll-like receptor 9 (TLR9) agonist	NCT02443935	University of Aarhus	Phase Ib/Ia	EBioMedicine. 2019 Jul 9. pii: S2352-3964(19)30440-2. AIDS. 2019 Mar 29 Clin Infect Dis. 2017 Mar 9
Poly-ICLC (TLR3 agonist)	NCT02071095	Nina Bhardwaj, MD/Campbell Foundation/Oncovir, Inc.	Phase I/II	Front Immunol. 2019 Apr 9;10:725.

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
TOLL-LIKE RECEPTOR AGONISTS (Cont.)				
vesatolimod (TLR7 agonist) in ART-treated HIV controllers	NCT03060447	Gilead Sciences	Phase Ib	Eur J Immunol. e2350809. Strategies for an HIV Cure 2023, Abstract PP24 CROI 2023, Abstract 437 EACS 2021 , Abstract PE2/1 IAS 2021, Abstract OAA0304 (video) Sci Transl Med. 2021 Jun 23;13(599): eabg3071. CROI 2020, Abstract 40 , Webcast
vesatolimod (formerly GS-9620) (TLR7 agonist)	NCT02858401	Gilead Sciences	Phase Ib	Eur J Immunol. e2350809. CROI 2024, Abstract 542 CID, ciaa1534 IAS 2019, Abstract WEAA0304 (slides)
vesatolimod (TLR7 agonist drug interaction study)	NCT05458102	Gilead Sciences	Phase I	Terminated: Sponsor decision to change the clinical development plan (not based on efficacy or safety concerns)
TRADITIONAL CHINESE MEDICINE				
Triptolide wilfordii	NCT02219672	Peking Union Medical College	Phase III	N/A
TREATMENT INTENSIFICATION/EARLY TREATMENT				
enfuvirtide	NCT00051831	NIAID	Not listed	J Infect Dis. 2010 Jan 15;201(2):293–6
enfuvirtide	NCT00334022	Canadian Immunodeficiency Research Collaborative	Not listed	N/A

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
TREATMENT INTENSIFICATION/EARLY TREATMENT (Cont.)				
New Era Study: Treatment with multi-drug class (MDC) HAART	NCT00908544	MUC Research GmbH	Not listed	Front Immunol. 2018 Apr 30;9:811
PLUS: Pilot study on the effect of adding raltegravir +/- a second drug on HIV levels in the gut	NCT00884793	University of California, San Francisco	Not listed	J Infect Dis. 2010 Nov 15;202(10):1553-61 AIDS. 2010 Oct 23;24(16):2451-60
Anti-HIV medications for people with recent HIV acquisition	NCT00106171	NIAID	Phase IV	PLoS One. 2015 10(11):e0143259
Antiretroviral regime for viral eradication in newborns	NCT02712801	National Center for Women and Children's Health, China CDC	Phase IV	N/A
DIORR: Dolutegravir impact on residual replication	NCT02500446	University of Melbourne	Phase IV	The Lancet HIV, April 8, 2018 CROI 2018, Abstract 71, Webcast
DRONE: Impact of starting a dolutegravir-based regimen on HIV-1 proviral DNA reservoir of treatment naïve and experienced patients	NCT02370979	University Hospital, Strasbourg, France	Phase IV	N/A
LEOPARD: Latency and early neonatal provision of antiretroviral drugs clinical trial	NCT02431975	Columbia University	Phase IV	PLoS Pathog. 2022;18(8):e1010751 CID, ciab586 J Clin Med. 2021 May 12;10(10):2074. EClinicalMedicine 18 (2020) 100241
P25-INACTION: Implication for strategies of long term control of viral replication in patients with primary HIV infection	NCT04225325	Adriano Lazzarin, MD	Phase IV	JAA. 64(2):107200. J Med Virol. 2023 Sep;95(9):e29114. EACS 2021, Abstract BPD4/3
ANRS 147 OPTIPRIM: Optimization of primary HIV-1 infection treatment	NCT01033760	Inserm-ANRS	Phase III	PLoS One. 2013; 8(5): e64219. PLoS One. 2013; 8(3): e59767 IAS 2013, Abstract WEAB0101

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
TREATMENT INTENSIFICATION/EARLY TREATMENT (Cont.)				
maraviroc	NCT00808002	Germans Trias i Pujol Hospital	Phase III	AIDS. 2014 Jan 28;28(3):325–34
raltegravir + maraviroc	NCT00935480	Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer	Phase III	N/A
raltegravir	NCT00554398	Germans Trias i Pujol Hospital	Phase III	Antivir Ther. 2012;17(2):355–64
tenofovir/emtricitabine + dolutegravir or tenofovir/emtricitabine + darunavir/cobicistat	NCT02987530	Inserm/ANRS	Phase III	N/A
VIRECURE: Impact of extremely early ART to reduce viral reservoir & induce functional cure of HIV infection	NCT02588820	David Garcia Cinca, Hospital Clinic of Barcelona	Phase III	EACS 2019, Abstract PE38/2
Intense acute infection study	NCT01154673	University of Toronto	Phase II/III	J Virol. 93(6): e01832-18. OFID 2(4): ofv138.
EDIT: Effect of dolutegravir intensification on HIV-1 reservoirs	NCT05351684	University of Liege	Phase II	CROI 2023, Abstract 429
maraviroc	NCT00795444	Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal/Pfizer	Phase II	AIDS. 2013 Aug 24; 27(13):2081-8. PLoS One. 2011; 6(12):e27864
peginterferon alfa-2a (Pegasys)	NCT00594880	Wistar Institute	Phase II	EBioMedicine. 2020 Aug 19;59:102945. J Infect Dis. 2013 Jan 15; 207(2): 213–222
peginterferon alfa-2b	NCT01935089	University of Pennsylvania/Wistar Institute	Phase II	AIDS Res Hum Retroviruses. 2020 Dec 15. CROI 2017, Poster abstract 326
peginterferon alfa-2b	NCT02227277	Wistar Institute	Phase II	HIV Persistence Workshop 2019, Abstract PP 4.1 (see abstract book) CROI 2019, Abstract 136 , Webcast

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org

Research Toward a Cure June 17, 2024

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
TREATMENT INTENSIFICATION/EARLY TREATMENT (Cont.)				
raltegravir	NCT00520897	Canadian Immunodeficiency Research Collaborative	Phase II	AIDS. 2012 Jan 14;26(2):167-74
raltegravir	NCT00807443	Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal	Phase II	AIDS. 2012 Sep 24;26(15):1885-94
Viral suppression after analytic treatment interruption in Thai patients who initiated HAART during acute HIV infection	NCT02614950	South East Asia Research Collaboration with Hawaii	Phase II	Nat Med. 2018 Jul;24(7):923-926. CROI 2017, Abstract 124 , Webcast
alpha interferon intensification	NCT01295515	NIAID	Phase I/II	N/A
indinavir + zidovudine + lamivudine + nevirapine	NCT00001644	NIAID	Phase I	N/A

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org